<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2385">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04497324</url>
  </required_header>
  <id_info>
    <org_study_id>PER-016-20</org_study_id>
    <secondary_id>20997</secondary_id>
    <nct_id>NCT04497324</nct_id>
  </id_info>
  <brief_title>PERUCONPLASMA: Evaluating the Use of Convalescent Plasma as Management of COVID-19</brief_title>
  <official_title>PERUCONPLASMA: Randomized Clinical Trial to Evaluate Safety and Efficacy of the Use of Convalescent Plasma in Hospitalized Patients With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad Peruana Cayetano Heredia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidad Peruana Cayetano Heredia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open label controlled clinical trial to evaluate the safety and efficacy of the use of&#xD;
      convalescent plasma in hospitalized patients with COVID-19 infection. This study will have&#xD;
      two arms, one arm will receive convalescent plasma plus standard of care, and the other arm&#xD;
      will receive standard of care only. Adults older than 18 years old, hospitalized with&#xD;
      diagnosis of COVID-19 confirmed by a laboratory test (molecular or serology), with severe or&#xD;
      life-threatening disease, will be included to the study after obtaining inform consent by the&#xD;
      patient of a direct family member. Participants will be then randomized 1:1 to the&#xD;
      experimental and the control groups.&#xD;
&#xD;
      Participants at the experimental group will receive 1 to 2 units of ABO compatible COVID-19&#xD;
      convalescent plasma (200 ml to 250 ml each) within 48 hours, in addition to the standard of&#xD;
      care. Participants at the control group will receive standard of care. Safety of convalescent&#xD;
      plasma administration will be evaluated, as well as other indicators of clinical efficacy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 21, 2020</start_date>
  <completion_date type="Anticipated">May 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Transfusion-related Serious Adverse Events</measure>
    <time_frame>14 days after randomization</time_frame>
    <description>Incidence of transfusion-related Serious Adverse Events, according to the Hemovigilance Module Surveillance Protocol v2.5.2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause in-hospital mortality</measure>
    <time_frame>30 days after randomization</time_frame>
    <description>Death during hospitalization within the first 30 days after enrollment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>30 days after randomization or until hospital discharge, whatever comes first</time_frame>
    <description>Number of days from date of enrollment to date of discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of ICU stay</measure>
    <time_frame>30 days after randomization or until hospital discharge, whatever comes first</time_frame>
    <description>Number of days from date of admission to the ICU to date of discharge from ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need of invasive mechanical ventilation</measure>
    <time_frame>30 days after randomization or until hospital discharge, whatever comes first</time_frame>
    <description>Requirement of invasive mechanical ventilation (Yes/No). Evaluated only for those participants that were on non-invasive ventilatory support at time of randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of mechanical ventilation</measure>
    <time_frame>30 days after randomization or until hospital discharge, whatever comes first</time_frame>
    <description>Number of days from date of intubation to date of successful extubation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Improvement at 14 days</measure>
    <time_frame>At 3, 14 and 30 days after randomization</time_frame>
    <description>Improvement of 2 or more points in the WHO progression scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of 1 to 2 units of convalescent plasma (200 ml to 250 ml, each), within 48 hours, plus standard of care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard of care</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Convalescent plasma</intervention_name>
    <description>Administration of 1 to 2 units of convalescent plasma (200 ml to 250 ml, each), within 48 hours, plus standard of care.</description>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Hospitalized 18 years old or older patient with COVID-19 disease, confirmed by a&#xD;
             molecular test or a serologic test, along with a typical COVID-19 clinical&#xD;
             presentation.&#xD;
&#xD;
          -  Severe or critical disease caused by COVID-19 Severe disease is defined as 2 or more&#xD;
             of the following criteria:&#xD;
&#xD;
               -  Respiratory frequency &gt;22&#xD;
&#xD;
               -  O2 saturation ≤93%&#xD;
&#xD;
               -  PaO2 50mmHg&#xD;
&#xD;
               -  PaO2/FiO2 &lt;300&#xD;
&#xD;
          -  Or critical disease with one or more of the following criteria:&#xD;
&#xD;
               -  Respiratory insufficiency with requirement of mechanical ventilation within the&#xD;
                  last 72hours&#xD;
&#xD;
               -  Shock&#xD;
&#xD;
          -  Inform consent signed by patient or direct family member.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindication for transfusion (history of TRALI or TACO, history of anaphylaxis to&#xD;
             blood components&#xD;
&#xD;
          -  Multiorgan failure, defined by a SOFA score of &gt;5&#xD;
&#xD;
          -  hemodynamically unstable, with mean arterial pressure &lt;60 mmHg, refractory to&#xD;
             vasopressors use&#xD;
&#xD;
          -  Uncontrolled concomitant infection&#xD;
&#xD;
          -  Disseminated intravascular coagulation&#xD;
&#xD;
          -  Myocardial infarction&#xD;
&#xD;
          -  Acute coronary disease&#xD;
&#xD;
          -  Patient on dialysis&#xD;
&#xD;
          -  Intracranial bleeding active within the last 7 days&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fiorella Krapp Lopez, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidad Peruana Cayetano Heredia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patricia Garcia Funegra, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidad Peruana Cayetano Heredia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fiorella Krapp Lopez, MD, MSc</last_name>
    <phone>(511) 3190000</phone>
    <phone_ext>201353</phone_ext>
    <email>fiorella.krapp@upch.pe</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Patricia J Garcia Funegra, MD, MSc</last_name>
    <email>patricia.garcia@upch.pe</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Cayetano Heredia</name>
      <address>
        <city>Lima</city>
        <zip>15102</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Coralith Garcia, M.D.</last_name>
      <email>coralith.garcia@upch.pe</email>
    </contact>
    <investigator>
      <last_name>Coralith Garcia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karla Tafur, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brian Delfin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Diana Condezo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karol Lipa, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Nacional Hipolito Unanue</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alonso Soto, MD</last_name>
      <email>sotosolari@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Liliana Chambi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Johan Azañero, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alonso Soto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Peru</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>July 31, 2020</study_first_submitted>
  <study_first_submitted_qc>July 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 4, 2020</study_first_posted>
  <last_update_submitted>March 15, 2021</last_update_submitted>
  <last_update_submitted_qc>March 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Convalescent plasma</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

